BioCardia, Inc. (BCDA) Free cash flow
- Free cash flow · 12 months (USD): Value $-7.57M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-7.57M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-7.56M − $9.00K ≈ $-7.57M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-7.56M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.03× | Operating cash flow / net income. Period ending 2026-06-30. $-7.56M ÷ $-7.34M ≈ 1.03× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -7.56M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 9.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -7.57M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -7.34M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-7.57M | (m) | $-7.56M | $9.00K | (m) | (m) | (m) | $-7.34M | (m) | (m) | (m) | 1.03× |
| 2026-03-31 | $-7.49M | (m) | $-7.48M | $10.00K | (m) | (m) | (m) | $-7.78M | (m) | (m) | (m) | 0.96× |
| 2025-12-31 | $-7.44M | (m) | $-7.44M | $7.00K | (m) | (m) | (m) | $-8.23M | (m) | (m) | (m) | 0.90× |
| 2025-09-30 | $-7.51M | (m) | $-7.51M | $2.00K | (m) | (m) | (m) | $-8.54M | (m) | (m) | (m) | 0.88× |
| 2025-06-30 | $-8.46M | (m) | $-8.45M | $4.00K | (m) | (m) | (m) | $-8.79M | (m) | (m) | (m) | 0.96× |
| 2025-03-31 | (m) | (m) | $-8.11M | (m) | (m) | (m) | (m) | $-8.39M | (m) | (m) | (m) | 0.97× |
| 2024-12-31 | $-8.03M | (m) | $-8.03M | $6.00K | (m) | (m) | (m) | $-7.95M | (m) | (m) | (m) | 1.01× |
| 2024-09-30 | $-7.31M | (m) | $-7.30M | $5.00K | (m) | (m) | (m) | $-7.72M | (m) | (m) | (m) | 0.95× |
| 2024-06-30 | $-7.11M | (m) | $-7.11M | $3.00K | (m) | (m) | (m) | $-8.56M | (m) | (m) | (m) | 0.83× |
| 2024-03-31 | $-8.95M | (m) | $-8.94M | $2.00K | (m) | (m) | (m) | $-10.34M | (m) | (m) | (m) | 0.87× |
| 2023-12-31 | $-9.99M | (m) | $-9.97M | $12.00K | (m) | (m) | (m) | $-11.57M | (m) | (m) | (m) | 0.86× |
| 2023-09-30 | $-11.13M | (m) | $-11.12M | $14.00K | (m) | (m) | (m) | $-12.53M | (m) | (m) | (m) | 0.89× |
| 2023-06-30 | $-10.74M | (m) | $-10.71M | $28.00K | (m) | (m) | (m) | $-13.01M | (m) | (m) | (m) | 0.82× |
| 2023-03-31 | $-10.26M | (m) | $-10.21M | $51.00K | (m) | (m) | (m) | $-12.08M | (m) | (m) | (m) | 0.84× |
| 2022-12-31 | $-10.63M | (m) | $-10.56M | $70.00K | (m) | (m) | (m) | $-11.91M | (m) | (m) | (m) | 0.89× |
| 2022-09-30 | $-10.65M | (m) | $-10.54M | $109.00K | (m) | (m) | (m) | $-12.34M | (m) | (m) | (m) | 0.85× |
| 2022-06-30 | $-11.29M | (m) | $-11.18M | $115.00K | (m) | (m) | (m) | $-11.99M | (m) | (m) | (m) | 0.93× |
| 2022-03-31 | $-11.51M | (m) | $-11.40M | $118.00K | (m) | (m) | (m) | $-12.98M | (m) | (m) | (m) | 0.88× |
| 2021-12-31 | $-10.48M | (m) | $-10.37M | $116.00K | (m) | (m) | (m) | $-12.62M | (m) | (m) | (m) | 0.82× |
| 2021-09-30 | $-10.88M | (m) | $-10.81M | $75.00K | (m) | (m) | (m) | $-12.15M | (m) | (m) | (m) | 0.89× |
| 2021-06-30 | $-11.85M | (m) | $-11.77M | $78.00K | (m) | (m) | (m) | $-13.29M | (m) | (m) | (m) | 0.89× |
| 2021-03-31 | $-11.30M | (m) | $-11.25M | $54.00K | (m) | (m) | (m) | $-13.38M | (m) | (m) | (m) | 0.84× |
| 2020-12-31 | $-12.39M | (m) | $-12.36M | $32.00K | (m) | (m) | (m) | $-15.00M | (m) | (m) | (m) | 0.82× |
| 2020-09-30 | $-12.23M | (m) | $-12.20M | $34.00K | (m) | (m) | (m) | $-15.52M | (m) | (m) | (m) | 0.79× |
| 2020-06-30 | $-10.10M | (m) | $-10.06M | $31.00K | (m) | (m) | (m) | $-15.46M | (m) | (m) | (m) | 0.65× |
| 2020-03-31 | $-10.07M | (m) | $-9.97M | $96.00K | (m) | (m) | (m) | $-15.64M | (m) | (m) | (m) | 0.64× |
| 2019-12-31 | $-9.59M | (m) | $-9.45M | $146.00K | (m) | (m) | (m) | $-14.71M | (m) | (m) | (m) | 0.64× |
| 2019-09-30 | $-9.59M | (m) | $-9.44M | $159.00K | (m) | (m) | (m) | $-14.85M | (m) | (m) | (m) | 0.64× |
| 2019-06-30 | $-10.12M | (m) | $-9.97M | $144.00K | (m) | (m) | (m) | $-14.60M | (m) | (m) | (m) | 0.68× |
| 2019-03-31 | $-10.61M | (m) | $-10.50M | $116.00K | (m) | (m) | (m) | $-14.07M | (m) | (m) | (m) | 0.75× |
| 2018-12-31 | $-11.13M | (m) | $-11.07M | $66.00K | (m) | (m) | (m) | $-13.99M | (m) | (m) | (m) | 0.79× |
| 2018-09-30 | $-10.43M | (m) | $-10.35M | $80.00K | (m) | (m) | (m) | $-13.83M | (m) | (m) | (m) | 0.75× |
| 2018-06-30 | $-10.20M | (m) | $-10.12M | $82.00K | (m) | (m) | (m) | $-13.29M | (m) | (m) | (m) | 0.76× |
| 2018-03-31 | $-9.51M | (m) | $-9.43M | $77.00K | (m) | (m) | (m) | $-13.02M | (m) | (m) | (m) | 0.72× |
| 2017-12-31 | $-8.81M | (m) | $-8.67M | $136.00K | (m) | $479.00K | (m) | $-12.31M | (m) | (m) | -1838.62% | 0.70× |
| 2017-09-30 | (m) | (m) | $-8.66M | (m) | (m) | $516.00K | (m) | $-12.40M | (m) | (m) | (m) | 0.70× |
| 2017-06-30 | (m) | (m) | $-8.02M | (m) | (m) | $503.00K | (m) | $-12.66M | (m) | (m) | (m) | 0.63× |
| 2017-03-31 | (m) | (m) | $-7.05M | (m) | (m) | $535.00K | (m) | $-11.69M | (m) | (m) | (m) | 0.60× |
| 2016-12-31 | (m) | (m) | $-5.52M | (m) | (m) | $576.00K | (m) | $-10.31M | (m) | (m) | (m) | 0.54× |
| 2016-09-30 | (m) | (m) | $-10.25M | (m) | (m) | (m) | (m) | $-13.66M | (m) | (m) | (m) | 0.75× |
| 2015-12-31 | $-7.15M | (m) | $-7.02M | $125.00K | (m) | $904.00K | (m) | $-6.70M | (m) | (m) | -790.71% | 1.05× |
| 2014-06-30 | (m) | (m) | $132.00K | (m) | (m) | (m) | (m) | $165.00K | (m) | (m) | (m) | 0.80× |
| 2014-03-31 | (m) | (m) | $68.00K | (m) | (m) | (m) | (m) | $108.00K | (m) | (m) | (m) | 0.63× |
| 2013-12-31 | (m) | (m) | $27.00K | (m) | (m) | (m) | (m) | $19.00K | (m) | (m) | (m) | 1.42× |
| 2013-09-30 | (m) | (m) | $440.00K | (m) | (m) | (m) | (m) | $52.00K | (m) | (m) | (m) | 8.46× |
| 2013-06-30 | (m) | (m) | $385.00K | (m) | (m) | (m) | (m) | $473.00K | (m) | (m) | (m) | 0.81× |
| 2013-03-31 | (m) | (m) | $-298.00K | (m) | (m) | (m) | (m) | $335.00K | (m) | (m) | (m) | -0.89× |
| 2012-12-31 | $-310.00K | (m) | $-310.00K | $0.00 | (m) | (m) | (m) | $305.00K | (m) | (m) | (m) | -1.02× |
| 2012-09-30 | $-1.56M | (m) | $-1.56M | $0.00 | (m) | $59.00K | (m) | $-18.00K | (m) | (m) | -2650.85% | 86.89× |
| 2012-06-30 | $-1.42M | (m) | $-1.42M | $0.00 | (m) | $40.00K | (m) | $-1.04M | (m) | (m) | -3540.00% | 1.37× |
| 2012-03-31 | $-2.64M | (m) | $-2.56M | $85.00K | (m) | $23.00K | (m) | $9.93M | (m) | (m) | -11478.26% | -0.26× |
| 2011-12-31 | $-3.22M | (m) | $-3.09M | $137.00K | (m) | $12.00K | (m) | $9.66M | (m) | (m) | -26866.67% | -0.32× |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-5.35M | (m) | $-4.28M | $1.07M | (m) | $0.00 | (m) | $-11.51M | (m) | (m) | (m) | 0.37× |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |